Navigation Links
PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
Date:11/20/2007

BOSTON, Nov. 20 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL), a leading global bio/pharmaceutical services organization, has appointed Dr. Victor Kiri, formerly with GlaxoSmithKline, as Director of Pharmacoepidemiology within the Company's Clinical Research Services business. Dr. Kiri's responsibilities include advising clients in the design and conduct of comparative observational studies, offering epidemiological analysis for compounds in development, and guiding strategic decisions regarding future areas of research and product development.

"Regulatory pressures are increasing client demand for pharmacoepidemiological assessments and related studies as part of late phase clinical development," said Mark A. Goldberg, M.D., President of Clinical Research Services and Perceptive Informatics at PAREXEL International. "One of PAREXEL's strengths is our late phase development service offering that we call Peri-Approval Clinical Excellence or PACE. Dr. Kiri's in-depth experience in late phase study design and safety-related issues further expands our capabilities to provide clients with integrated pharmacoepidemiology and pharmacovigilance solutions."

"PAREXEL's PACE group has successfully implemented some of the largest and most complex trials of marketed products ever conducted, and I am pleased to be joining such a premier team of global experts," said Dr. Victor Kiri. "I look forward to contributing to PAREXEL's focused expertise in the area of pharmacoepidemiology, and working with clients to determine the right methods and approaches for their late phase studies."

Prior to joining PAREXEL, Dr. Kiri managed epidemiology research at GlaxoSmithKline. He previously served as a consultant on health outcomes to the U.K. Department of Health for more than 15 years. Dr. Kiri received an MSc degree in Operational Research from the University of Sussex and a Ph.D. from the University of Bradford, both located in the U.K. Dr. Kiri has been appointed as Adjunct Professor of Biostatistical Epidemiology at the University of Limerick in Ireland. His other academic appointments have included serving as a lecturer at the London School of Hygiene and Tropical Medicine and at the Department of Epidemiology at the University of Surrey, in the U.K. Dr. Kiri has been elected as a Chartered Statistician by the U.K. Royal Statistical Society.

Note: The International Society for Pharmacoepidemiology (ISPE) defines pharmacoepidemiology as the study of the utilization and effect of drugs in large numbers of people. ISPE defines epidemiology as the study of distribution and determinants of diseases in populations.

About PAREXEL International

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 64 locations throughout 51 countries around the world, and has approximately 7,000 employees. For more information about PAREXEL International visit http://www.PAREXEL.com.

This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the period ended September 30, 2007 as filed with the SEC on November 7, 2007, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.

Contacts:

Jennifer Baird,

Director of Public Relations

PAREXEL International

Tel: +781-434-4409

Email: Jennifer.Baird@PAREXEL.com

Rebecca Passo

SHIFT Communications

Tel : +617-779-1817

Email : rpasso@shiftcomm.com


'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
2. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
3. Cellectar Expands Clinical Management Team
4. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
7. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
8. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
11. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Feb. 11, 2016  NOIT™ Research LLC, a private, ... of Change" campaign to assist needy families in obtaining ... unit sold between February 10, 2016 and March 31, ... needy family. The NOIT is an auditory stimulus that ... develop language skills. Beth Shier , ...
(Date:2/11/2016)... 11, 2016 AAIPharma Services Corp./Cambridge Major ... manufacturing and development services for the pharmaceutical and ... and capacity in its Charleston, SC ... driven several recent investments. Charleston ... filling line with small-scale lyophilization. The site has ...
(Date:2/11/2016)... PORTLAND, Ore. , Feb. 11, 2016 ... to announce the acquisition of SolutionsRx, a full-service 340B ... hospitals. Along with providing traditional contract pharmacy services, SolutionsRx ... assist clients in navigating the complex 340B regulatory environment. ... Wellpartner. --> James R. Love , CEO ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... ... an Au Pair comes all the way around the world to provide child ... are often worried things won’t go well. More often than not, however, they find out ... the Year winner’s all commented how their Au Pairs have become a part of the ...
(Date:2/12/2016)... ... February 12, 2016 , ... The law firm of Morrow, Morrow, ... The purpose of these scholarships is to encourage applicants to pursue a degree ... employment within these two parishes. , “We have available jobs in St. Landry ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... Each year, ... will be held in Anaheim, CA at the Anaheim Convention Center. Almost 10,000 physical ... see new therapy products in action, learn more about their chosen field and network ...
(Date:2/12/2016)... ... February 12, 2016 , ... Itopia, a leader in cloud ... Clarity Intelligence Platform (CIP) into Cielo®, a discovery, migration and cloud orchestration engine. ... their small and medium business (SMB) clients. , In recent years, ...
(Date:2/12/2016)... ... ... Vail knee specialist Robert LaPrade, MD, PhD was named one of ... of physicians establishing, leading and partnering with ambulatory surgery centers across the United States. ... also known as an ASC, is a modern health care facility focused on providing ...
Breaking Medicine News(10 mins):